Thank was the much, first allogeneic MiNK we ago as us today, call. joining company quarterly clinical advanced invariant IPO earnings you or for Therapeutics thank you programs. and all cells or cells Kimberly, in as about XX off-the-shelf iNKT our an stand just months killer very pioneering, in natural most launched for and T three active
site our manufacturing patient our our product GMP these for and are healthy our needs of clinical We donors. potency potential in-house them And demonstrated isolate the scale the from cells we freezing. cells tumor-killing have them. can in that trials, Thus both at We shown can produce we've all when retains at after that suite. also
has data these in delivering clinical we isolating from conference to to three who share highly failed we infection. complications programs, considered to programs immunity system year. Currently, eliminate from patients most, focus is a patients the whose or cancer this and serious most immune expect Our prevent and on need them have them at cells active
with only of field, As the two diseases. which we their threat acquire iNKTs time at immunity a we a both At threats the immunity external COVID-XX. that arms immune both makes application properties pursuing pioneer faced our we of every has paces, to record-breaking in when and immunity modulate immediately natural cells distinct in are the adaptive cells. the growth background, natural not also responds that to and immunity, arms we to and that but innate of line are leverage critical of the system cells strength information them adapt in to immune-related which body's MiNK to like over advance because way By of iNKT of with of and defense. new science MiNK, This must unique or NK born appreciate and contribute T
rejection a such as So in cells is disease engineering in these allows what we are cells are a of cells. shown common without autoimmune A remarkable the and happens There is them this TCR. us when severely recipient. another disease, their receptor diabetes, healthy and cancer. or one feature the the to graft-versus-host are in deficient, This from ill and individual when limited models T-cell cells invariant these is everyone functional or humans, diseases, these not from no we've without observed or vivo? cells cells iNKT in in and preclinical and or without isolate What with cells development deliver iNKT heart of asthma individual, receptor to donor quantity patient
cancer pursuing our rejection. and help This disease other prevent and why iNKT could or therapies is prevent evidence actually have subsequently. patients accept actually cells graft-versus-host diseases. for we fact, that In immune-related we're suggest transplants They may iNKT immune-mediated to cell
cells and specifically focus, the effect, has that's in We solid our platform tumor developed have major expect cancers, significant these a MiNK a with to impact to achieve this.
including I'm For need internalization our across deliver affordable, position to our talking of in platforms, and solid our to now recent and discovery about engineering and cell progress, majority these deliver manufactured the able manufacturing scale. up be the tumor therapies our of cancers, were they patients. best tumors, the effective internal transformative GMP full at to capabilities set to benefits be for And
Dijk, antibodies, Officer and that including novel industry and at Scientific platforms who van and technology TCRs, veteran, commercial those Agenus. of Our built Dr. Bristol-Myers clinical is newly the given to bispecifics has dozens an and appointed Genmab Chief stage have Marc rise Squibb,
we therapy, cell Zhou those cell from more brings from expertise Joy manufacturing appointed of and Joy Takeda Head Dr. as and now MiNK. Manufacturing. and decades recently applying J&J, recently at Additionally, internally therapy Rubius, from she's here gene of
proprietary are scalable and platform These with XX,XXX doses billion nearly reagents are deliver in-house and programs platforms capacity. manufacturing our deliver Our to to more annually. doses own set X up than
proprietary these their can donors. than cryopreservation, retain Our from thus be and stored tumor and delivered a product And cells iNKT healthy process potential that killing reagents more cells they pure is internationally. enable lengthy XX% after
Our the currently clinical process allo-iNKTs to for scalable internationally. of need native the our available they the distributed moment are GMP manufacturing of readiness trials manufacturing They're patient to team them. sites and and first known GMP a delivered achievement for field. scale. in a completion our is reproducible a internally that recognized and remarkable with manufacturing iNKT cell recently the in-house industrialization infrastructure manufacturing facilitate at We the has to This process our runs
and was three the facility AgenT-XXX cell active our program, without commonly cells requirements progress therapy production. Today, experienced cell completed allo is INKT of completed lead capital-intensive also outfitted therapy was necessary clinical in manufacturing team. already This for this an native an with programs. Importantly, an
readouts conference next this months. expected X/X or solid OPDIVO the May combination Data are tumor KEYTRUDA a patients in study alone year. in major iNKTs and Our Phase launched few in of with with at cancers of within
reduction of as known with liver a presentations patient SITC metastatic Society including data last in disease year. encouraging rectal otherwise the of Our builds Cancer, cancer, refractory for on from the signals, Immunotherapy
Our leading can iNKT and lungs with features the cells. tumors that scientist, the also lipid support other responses. that and to ability These of that persist. initiation cells cells T and travel advantage benefit ligand, bring iNKT like invariant enables TCR that gamma/delta are durable cancer. take in natural recognizes cells over the of Boussios, the types will cell unique bone presented potential contribute iNKTs liver, the of they to cell which their We to benefit these CDXd like data patients killer cell's and they marrow. believe showed They to protective Dr.
to the importantly, INKTs response. response. invariant receptors, So to express also cell naturally engineered NK-cell-like they them activating NK advance importantly, TCR, can about to effectively express retain iNKTs you think cytotoxic And if don't home receptors, they able initiate potent they with so need to inhibitory where making their a that NK-cell go. they're and
modulate microenvironment relapse/refractory Lastly, cells native iNKT evaluating We're T also cells. NK cells transactivate can and and tumor in multiple the AgenT-XXX myelomas. allo-iNKTs
treatments has is in been and myeloma, the somewhat the require still made lymphodepletion While cytotoxic with underwhelming. CAR-T durability BCMA therapies progress
the of who progress therapy BCMA thirds following patients exhibit two antigen. still CAR-T Importantly, BCMA
cancer iNKTs without also naturally and active ligand, very treated, lung The or in critical This and secondary lines cells in AgenT-XXX or and cases meaning later T And These stabilization other million type. administered reported in active cytokines male to tissue. our biomarkers that in can months INKT that's dose to of of other protecting cells NK feature tumor-killing lengthy in believe that data In will cells in importantly, rapid this cells lymphodepletion, more earliest was and defense protein, one epithelial expect and type. multi-myeloma cells are home recruit durability patient, suppression we reduction rich CDXd related is tumor marrow influenza, we in be first The tumor this greater pneumonia XX% improve will these ongoing controlling of patients in M-spike experienced earliest are XX-year-old XXX response without secrete exceeding distress, cells this months. stabilization we year. cells the that respiratory a and acute infection. of a to XX particularly the we of and disease treated bone antigen is highly are beyond reduction lipid diseases. than treated of a in our it's XX also will in engineering. plan this present and our with severe per Enrollment disease cells expressed is tumor COVID
heart such, to brought therapy help of the As our during we the pandemic.
trial in of benefits cohort Phase important of These include and year, to all mitigate were evaluation, before plan models. AgenT-XXX. we COVID-XX, our data which MERS elderly, data in in and Our distressed secondary X this well completed data other our as benefit of mechanical of data harmful as respiratory end expanded shown We preclinical present previously to XX preclinical reported to therapies. influenza. viral immune survival predominantly ARDS our extend will these the infections, DARPA, survival in Advanced SARS, XX% or treat Phase consequences cells first Defense can acute as of disregulations iNKT our X In investigate against release effectively that the viral led Projects CoV-X by These patients. and the and we funding influenza, Research have cells identified of pneumonia cells had Agency, syndrome and for to selectable including secondary survival all Agent-XXX patients exceeding and failed were available ventilation on has
of is in future to including variant and next mitigating with evaluate AgenT-XXX, collaboration approach potential Our a possibility threats will agnostic look to mitigation. current the negotiations, contract DARPA disease step with what supporting our and like, we're pandemic with thrilled DARPA
We provide later this our details in year. potential collaboration expect of more to
profile signals cytokine deliver clinical including a now with that iNKT cell no TCRs also cells the a be of observed iNKT wholly and in we've owned billion or dose. can engineered to these next-generation to with our per to host release able XXX spans we've and syndrome, addition doses without activity, favorable We've cells MiNK's pipeline In bispecific programs, the at CARs, lymphodepletion. patients also engager. safety been X administered immune neurotoxicity up of demonstrated diseases
we Agenus, iNKT potential BCMA-CAR-iNKT to and selection This novel best-in-class an these with combinations our activities agent are CAR programs solid with Through includes both Our the year. iNKT Data upcoming Agenus' an uniquely stromal-targeting our this target on relationship targeting and cells are CAR and likes our IND-enabling meeting launch in presentation immune-activating to First positioned plan iNKTs tumors. data and present balstilimab. stromal for we on
in immune the with priority in system. of and bladder and appreciate can lung. registration, Our in such our standard Klaskin including allogeneic our call on lead the At to rapid its the your modulating financials. checkpoint with MiNK, to Christine? agents is we with cancers AgenT-XXX therapy time, I turn focused combination as of now and over cancers, antibodies to delivering native liver, form of over eliminate in alone combination remain approaches advance that will to go off-the-shelf I Christine to care diseases
